Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$0.11 - $0.22 $38 - $76
-348 Reduced 1.33%
25,744 $3,000
Q3 2023

Nov 14, 2023

BUY
$0.11 - $1.76 $1,669 - $26,711
15,177 Added 139.05%
26,092 $3,000
Q2 2023

Aug 14, 2023

BUY
$1.25 - $1.92 $10,625 - $16,320
8,500 Added 351.97%
10,915 $13,000
Q1 2023

May 09, 2023

SELL
$1.29 - $2.46 $23,876 - $45,532
-18,509 Reduced 88.46%
2,415 $5,000
Q4 2022

Feb 10, 2023

BUY
$1.2 - $1.83 $7,606 - $11,600
6,339 Added 43.46%
20,924 $27,000
Q3 2022

Nov 10, 2022

BUY
$0.61 - $1.03 $1,620 - $2,736
2,657 Added 22.28%
14,585 $12,000
Q2 2022

Aug 15, 2022

BUY
$0.93 - $1.9 $9,915 - $20,257
10,662 Added 842.18%
11,928 $12,000
Q1 2022

May 12, 2022

SELL
$1.85 - $2.75 $6,737 - $10,015
-3,642 Reduced 74.21%
1,266 $2,000
Q4 2021

Feb 14, 2022

BUY
$2.19 - $4.07 $8,933 - $16,601
4,079 Added 492.04%
4,908 $11,000
Q3 2021

Nov 15, 2021

BUY
$3.67 - $5.8 $418 - $661
114 Added 15.94%
829 $3,000
Q2 2021

Aug 16, 2021

SELL
$4.65 - $6.42 $59,310 - $81,887
-12,755 Reduced 94.69%
715 $4,000
Q1 2021

May 17, 2021

BUY
$5.11 - $9.24 $48,095 - $86,966
9,412 Added 231.94%
13,470 $89,000
Q4 2020

Feb 16, 2021

SELL
$4.36 - $6.51 $32,194 - $48,069
-7,384 Reduced 64.53%
4,058 $23,000
Q3 2020

Nov 16, 2020

BUY
$4.7 - $12.06 $20,675 - $53,051
4,399 Added 62.46%
11,442 $54,000
Q2 2020

Aug 13, 2020

BUY
$5.18 - $14.81 $31,613 - $90,385
6,103 Added 649.26%
7,043 $82,000
Q1 2020

May 15, 2020

SELL
$3.5 - $13.77 $2,810 - $11,057
-803 Reduced 46.07%
940 $5,000
Q4 2019

Feb 07, 2020

BUY
$6.21 - $14.02 $9,445 - $21,324
1,521 Added 685.14%
1,743 $24,000
Q3 2019

Nov 05, 2019

BUY
$5.2 - $8.68 $1,029 - $1,718
198 Added 825.0%
222 $2,000
Q2 2019

Aug 13, 2019

BUY
$5.65 - $7.5 $135 - $180
24 New
24 $0
Q1 2019

May 14, 2019

SELL
$3.35 - $8.27 $7,098 - $17,524
-2,119 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$3.23 - $8.7 $6,844 - $18,435
2,119 New
2,119 $7,000

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.